PPD acquires healthcare research biz Evidera

handshake

Global CRO PPD joined forces with research-based consulting company Evidera. The Bethesda, MD-based company helps pharmas and biotechs demonstrate value in the research stages.

The companies didn’t reveal the monetary terms of the agreement, but Evidera will become a wholly owned subsidiary of the CRO giant. The addition of the firm should give PPD access to capabilities and expertise that promises a leg up in the pharma and biotech space.

“Our acquisition of Evidera demonstrates PPD’s commitment to strategic investments that enable our clients to advance the generation of real-world evidence to more efficiently deliver life-changing therapies that improve health,” PPD CEO David Simmons said. “We are dedicated to providing our clients a superior integration of scientific knowledge, technology and high-quality delivery to maximize the productivity of their R&D investments and to accelerate patient access to life-changing therapies.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Evidera will continue to operate its offices in North America and Europe and serve many of the top biopharma companies. The deal should close within the next few months, according to a release.

- here's the release

Read more on

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

The Mayo Clinic tapped data analytics firm nference to build out an AI-powered engine to collate its years of clinical records and pathology work.

At the annual J.P. Morgan Healthcare Conference, major CRO Charles River Laboratories and Takeda announced a new preclinical tie-up.